The Ministry of HEALTH has registered the drug L-thyroxine, which is taken with a lack of thyroid hormones, produced by the Russian pharmaceutical company Renewal (PFC "Update"), TASS reports with reference to the press service of the department.
“This will allow the company to launch the production of the most important drug for the treatment of thyroid diseases, it is effective in the fight against severe disorders of the endocrine system,” the department explained.
The pharmaceutical company promises that its capacity will allow, if necessary, at the initial stage to reach the volume of 500,000 packs of L-thyroxine per month, and subsequently - 1 million packs. It is planned to launch the production of the drug within a month. The drug will be supplied to the market in two dosages - 50 micrograms and 100 micrograms.
L-thyroxine (international non-proprietary name "levothyroxine sodium") is a synthetic thyroid hormone preparation included in the list of essential drugs.
In early March, residents of Moscow, Kaliningrad, Tyumen, St. Petersburg, Sakhalin and other regions reported a shortage of drugs based on L-thyroxine in pharmacies.